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Introduction
“When you become a person of pain, you will start on a journey
that you will never forget and one of permanent change. The
change that is thrust upon you will be unwanted, unpredictable,
filled with uncertainty, and one that will be very destructive to
your life if you do not take steps [to] control what will quickly
become [an] out of control situation.” 1

Beginning in the late 1990s, the United States began to feel the
effects of what has recently been declared a “public emergency” by the
Department of Health and Human Services – the opioid epidemic.2 The
Government believed that the increase in opioid misuse, abuse, and
1.

Testimonials,
CHRONIC
PAIN,
http://www.thechronicpain.com/
testimonials-1 (last visited Nov. 11, 2017) (citing a testimonial by Thomas
Porter).

2.

What is the U.S. Opioid Epidemic?, U.S. DEP’T HEALTH & HUM. SERVS.,
https://www.hhs.gov/opioids/about-the-epidemic/index.html
(last
visited Feb. 17, 2019).
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overdose was directly related to the number of opioid prescriptions
written by doctors.3 State legislatures then responded by passing laws
that imposed strict prescribing limitations and harsh punishment for
those doctors that broke the law and disregarded the newly set
limitations.4 As a result, doctors became fearful of creating addicts and
breaking the law. Thus began the decline in the practice of prescribing
opioids, even for those who suffered from chronic pain.5
Meet Judy – a seventy-three-year-old, two-time cancer survivor.6 In
2008, Judy was diagnosed with esophageal cancer. To combat the
advanced-stage cancer, she underwent surgery to remove the cancerous
portion of her esophagus. She then held tough through rounds upon
rounds of chemotherapy. As a result, Judy suffered from severe chronic
pain. To help, Judy’s oncologist prescribed OxyContin, a narcotic pain
reliever that is used to treat moderate to severe pain.7 Though she took
it as prescribed, as time went on, she needed to take more pills to
achieve the same amount of pain relief. Then, it happened again. Two
years later, after beating esophageal cancer, Judy was diagnosed with
liver cancer. She, again, endured multiple rounds of chemotherapy. As
a result of the pain she suffered, Judy’s oncologist prescribed more
OxyContin. She continued to take the drug as directed, but continually
required a higher dose to achieve adequate pain relief. Thankfully, Judy
has been in remission since 2011. However, one effect of the cancers has

3.

Evan D. Anderson & Corey S. Davis, Breaking the Cycle of Preventable
Suffering, 24 TEMP. INT’L & COMP. L.J. 329, 359-60 (2010).

4.

See e.g., ALASKA STAT. § 08.36.355 (2018) (enacted 2017); ALASKA STAT.
§ 08.36.315 (2018) (enacted 2017); H.B. 333, 2017 Gen. Assemb., Reg.
Sess. (Ky. 2017); N.J. ADMIN CODE § 13:45H-7.5 (2019) (enacted 2012);
N.J. ADMIN CODE § 13:45H-7.20 (2019) (enacted 2013); Act 122, 2016
Gen. Assemb., Reg. Sess. (Pa. 2016); Act 125, 2016 Gen. Assemb., Reg.
Sess. (Pa. 2016); Amy J. Dilcher, Damned If They Do, Damned If They
Don’t: The Need for a Comprehensive Public Policy to Address the
Inadequate Management of Pain, 13 ANNALS HEALTH L. 81, 104-05 (2004);
Ashley Bruce Trehan, Fear of Prescribing: How the DEA is Infringing
on Patients’ Right Palliative Care, 61 U. MIAMI L. REV. 961, 976
(2007).

5.

See Dilcher, supra note 4, at 85; Rima J. Oken, Curing Healthcare
Providers’ Failure to Administer Opioids in the Treatment of Severe
Pain, 23 CARDOZO L. REV. 1917, 1923 (2002).

6.

The information included in this paragraph comes from an interview
conducted with my maternal grandmother. She does not wish for any
other identifying information to be included in the article.

7.

OxyContin, DRUGS, https://www.drugs.com/oxycontin.html (last visited
Mar. 19, 2018).
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not subsided – the pain. To this day, Judy suffers from chronic pain
and continually needs OxyContin.8
Recently, the Pennsylvania legislature has taken steps to restrict
opioid prescribing practices. In particular, Pennsylvania issued
prescribing guidelines that recommended 100 mg per day as the
maximum dose.9 Judy’s doctor, in response to the guideline publication
and fear of scrutiny, informed Judy that he would have to decrease the
amount of OxyContin she receives. For Judy, this was frightening
because 100 mg was not enough and Judy now struggles to find a way
to adequately treat her chronic pain.
Unfortunately, Judy is not alone; approximately fifty million
Americans suffer from chronic pain.10 If access to opioid pain medication
is continually restricted or eliminated as a result of attempts to combat
the opioid epidemic, there can be devastating consequences for chronic
pain patients.11 It is time that the government reexamine its views on
the opioid epidemic and how to end it. Chronic pain patients are
unintentionally bearing the burden of new restrictive legislation.
Therefore, there is a heightened need for a centrally coherent and
comprehensive public health solution that addresses substance abuse,
while at the same time providing chronic pain patients with the relief
they need.12 Until a comprehensive strategy is implemented that reduces
harm while allowing providers to care for patients without undue
interference, chronic pain patients, rather than opioid abusers, will be

8.

Author’s interview with Judy Craday, in Corry, Pennsylvania (January
2018).

9.

OPIOID DISPENSING GUIDELINES, COMMONWEALTH OF PA. & THE PA.
PHARMACISTS ASS’N (2016), available at http://www.health.pa.gov/
My%20Health/Diseases%20and%20Conditions/AD/Documents/PA%20
Guidelines,%20on%20the%20Dispensing%20of%20Opioids.pdf.

10.

Chuck Weber, NIH Study Shows Prevalence of Chronic or Severe Pain in
U.S.
Adults,
AM.
PAIN
SOC’Y
(Aug.
18,
2015),
http://americanpainsociety.org/ about-us/press-room/nih-study-showsprevalence-of-chronic-or-severe-pain-in-u-s-adults.

11.

Kent Durning, No Pain No Gain?! Who Will Make the Greatest Sacrifices
in Curbing Opioid Analgesic Diversion and Abuse?, 93 KY. L.J. 199, 239
(2004-05).

12.

See Tessa Cheng & Kora DeBeck, Between a Rock and a Hard Place:
Prescription Opioid Restrictions in the Time of Fentanyl and Other Street
Drug Adulterants, 108 CAN. J. PUB. HEALTH 325, 326 (2017).
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the ones most affected by the government’s attempt to combat the
opioid epidemic.13
This Note will focus on restoring physician discretion and patient
autonomy by proposing a uniform Prescription Drug Monitoring
Program (“PDMP”) that may be adopted by state governments. If
adopted, a uniform PDMP will allow doctors to use their best judgment
when treating chronic pain patients while combatting the opioid
epidemic.
Part I of this Note will discuss the timeline and relevant statistics
surrounding the opioid epidemic that has overwhelmed the United
States in recent decades and the negative effects that the epidemic has
had on the treatment of chronic pain patients. Part II will discuss the
components of a PDMP and argue that a PDMP is the best approach
to combat the opioid epidemic while restoring physician discretion and
patient autonomy. Part III will discuss the current issues surrounding
state PDMPs, including: (1) failure to collect sufficient data; (2) failure
to effectively use collected data; (3) failure to distribute data across
state lines; and (4) consequences of improperly structured PDMPs. Part
III will also propose a uniform PDMP which incorporates the solutions
to the outlined problems.

I.
A.

The Opioid Epidemic and Its Effect on Chronic
Pain Patients
The Driving Force of Stringent Government Regulations – Opioids
and The Opioid Epidemic

Opioids are a class of drugs that includes synthetic opioids14 such
as heroin and oxycodone that are legally obtainable via prescription.15
Opioids work by chemically interacting with opioid receptors in the
body and brain, thus producing euphoria in addition to pain relief.
13.

Sarah Ruiz-Grossman, America’s Drug Overdose Death Rate Keeps
Getting Worse: CDC, HUFFINGTON POST (Nov. 7, 2017, 6:57 PM),
https://www.huffpost.com/entry/drug-overdose-death-rate-rise-2016cdc_n_5a0211d3e4b06ff32c940276; Robert J. Gatchel, Is Fear of
Prescription Drug Abuse Resulting in Sufferers of Chronic Pain Being
Undertreated, 10 EXPERT REV. NEUROPATHICS 637 (2014).

14.

Synthetic opioids are narcotic analgesic drugs that are manufactured in
chemical laboratories with a similar chemical structure to natural opiate
drugs. Natural opiates are harvested from poppies, and contain alkaloids
which have an analgesic effect. Synthetic opioids are manufactured using
chemicals other than opium-related alkaloids. Synthetic Opioids,
WORKPLACE TESTING, https://www.workplacetesting.com/definition/
3734/synthetic-opioids (last visited Mar. 15, 2018).

15.

Opioids, NAT’L INST. DRUG ABUSE, https://www.drugabuse.gov/drugsabuse/opioids. (last visited Nov. 15, 2017).
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Opioids are, generally thought of as highly addictive.16 But, opioid pain
relievers such as oxycodone, hydrocodone, codeine, and morphine, are
usually safe when taken as prescribed.17 However, opioids have been
misused, abused, and causing death for decades. The United States is,
and has been since the late 1990s, in the midst of an opioid crisis.18 In
fact, over the last decade, deaths attributable to synthetic opioid
overdoses have risen from approximately 3500 to 28,400.19 As a result,
the Center for Disease Control has declared the opioid crisis an
“epidemic.”20
In response, the Government began implementing legislation to
limit the number of opioids prescribed to patients across the country.
Though cracking down on prescribing practices of well-intentioned
physicians is not the best method to combat the opioid epidemic, the
government’s approach is not illogical. Beginning in 1991, the United
States saw a sharp increase in the number of opioid prescriptions
written by prescribers21 That year, “doctors wrote 76 million
prescriptions” for opioid painkillers, and “[b]y 2011, that number had
nearly tripled, to 219 million.”22 These figures troubled lawmakers
because during that time, the population of the United States increased
by sixteen percent and the amount of prescriptions written for some
opioids increased by over 1000%.23 In 2012, the doctors in twelve states
wrote more opioid prescriptions than the total number of patients

16.

Nancy R. Steer & Mollie A. Gass, Monitoring Controlled Substances:
Prescription Monitoring Programs as a Tool for Monitoring the
Prescription Drug Epidemic, 5 IN-HOUSE DEF. Q. 5, 6 (2016).

17.

COMMONWEALTH OF PA & THE PA PHARMACISTS ASS’N, supra note 9.

18.

CDC Fifty-State Survey of Doctor Shopping Laws and Patient
RISK
L.
(Nov.
16,
2017),
Prescription
Abuse,
MED.
http://medicallawperspectives.com/Content_Weekly/CDC-Fifty-StateSurvey-of-Doctor-Shopping-Laws-and-Patient-Prescription-Abuse.aspx
[hereinafter CDC Fifty-State Survey]; Dan Nolan & Chris Amico, How
Bad is the Opioid Epidemic?, PBS (Feb. 23, 2016), https://www.pbs.org/
wgbh/frontline/article/how-bad-is-the-opioid-epidemic/.

19.

Overdose Death Rates, NAT’L INST. DRUG ABUSE (Sept. 2017),
https://www.drugabuse.gov/related-topics/trends-statistics/overdosedeath-rates.

20.

Nolan & Amico, supra note 18.

21.

Id.

22.

Id.

23.

The statistics included in the article were from 1997 to 2011. The statistics
pertained to oxycodone sold by retail pharmacies. Nancy A. Melville,
Millions of Opioid Prescriptions Go to ‘Doctor Shoppers’, MEDSCAPE
(July 23, 2013), https://www.medscape.com/viewarticle/808266.
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treated; averaging more than one prescription per patient.24 Most
recently, in 2015, approximately 250 million prescriptions were written
for opioid painkillers which: (1) were enough for every American to be
medicated twenty-four hours a day for three weeks; and (2) further
solidified the United States’ position as the top consumer of opioids by
exceeding the per capita rate of other countries.25
Because opioids are regularly prescribed in the United States, the
rise in prescription painkiller misuse is often attributed to the increasing
supply and availability.26 Recent statistics show that there has been an
increase in the number of non-medical uses of opioid pain relievers.
Specifically, in 2010 study conducted by the National Household Survey
on Drug Abuse, about seven million people aged twelve and older
reported recreational use of prescription opioid pain relievers and that
number increased to 16.7 million in 2012.27
The sharp increase in opioid prescription painkiller misuse and
abuse is frightening because these practices often lead to drug overdoses

24.

The calculations looked at how many prescription opioids were prescribed
per 100 people. The following twelve states prescribed more than 100
prescriptions per 100 people (in order of severity): Alabama, Tennessee,
West Virginia, Kentucky, Oklahoma, Mississippi, Louisiana, Arkansas,
Indiana, Michigan, South Carolina, and Ohio. Nolan & Amico, supra note
18.

25.

The United States regularly consumes about 80% of the world’s opioids
which renders it the top opioid consumer in the world. See Elaine Cox,
The Hidden Victims of Opioid Epidemic, U.S. NEWS (June 22, 2017),
https://health.usnews.com/health-care/for-better/articles/2017-0622/the-hidden-victims-of-the-opioid-epidemic; White House Comm’n on
Combatting Drug Addiction and the Opioid Crisis, Draft Comm’n Interim
Report (2017), available
at https://www.whitehouse.gov/sites/
whitehouse.gov/files/ondcp/commission-interim-report.pdf [hereinafter
White House Comm’n]; Opioid Crisis: Five Ways to Tackle the U.S. Drug
Epidemic, BBC NEWS (Aug. 6, 2017), http://www.bbc.com/news/worldus-canada-40479686.

26.

Steer & Gass, supra note 16; Increased Drug Availability is Associated
with Increased Use and Overdose, NAT’L INST. DRUG ABUSE,
https://www.drugabuse.gov/publications/research-reports/relationshipbetween-prescription-drug-abuse-heroin-use/increased-drug-availabilityassociated-increased-use-overdose (last updated Jan. 2018).

27.

RESULTS FROM THE 2010 NATIONAL SURVEY ON DRUG USE AND HEALTH:
SUMMARY OF NATIONAL FINDINGS, U.S. DEP’T OF HEALTH & HUM.
SERVICES (Sept. 2011), available at https://www.samhsa.gov/data/
sites/default/files/NSDUHNationalFindingsResults2010-web/
2k10ResultsRev/NSDUHresultsRev2010.pdf.
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and quite possibly death.28 In recent years, prescription opioids have
been a driving-force in the fifteen-year increase in opioid overdose
deaths.29 Currently, forty-six people in the United States die every day
as a result of prescription opioid overdoses; those deaths constitute
about thirty-five percent of all overdose deaths annually.30 The
relationship between the increase in supply, misuse, and overdose
deaths seems to point to prescribers as the culprits, and at first glance
it seems sensible to restrict prescribers’ decision-making power. But,
what the government may not have considered when passing new
restrictive legislation was the effect it would have on those who need
access – chronic pain patients.
B.
1.

(Under)Treatment of Chronic Pain Patients and How the Opioid
Epidemic Has Affected Their Treatment
Undertreatment of Chronic Pain Patients Unrelated to the Effects of
the Opioid Epidemic

Chronic pain is the “most common and debilitating disorder” in the
United States.31 It affects one-third of Americans at some point in their
lives and is the most common cause of long-term disability.32 Chronic
28.

David Blumenthal & Shanoor Seervai, To Combat the Opioid Epidemic,
We Must Be Honest About Its Causes, HARV. BUS. REV. (Oct. 26, 2017),
https://hbr.org/2017/10/to-combat-the-opioid-epidemic-we-must-behonest-about-all-its-causes.

29.

See Kristin Finklea et al., Prescription Drug Monitoring Programs, CONG.
RESEARCH SERV. (May 24, 2014), https://fas.org/sgp/crs/misc/
R42593.pdf (“Nearly three out of four prescription drug overdoses are
caused by prescription painkillers or opioids”); Prescription opioid
overdoses are now twice as common as heroin and cocaine deaths
combined. See Melville, supra note 23. In 2011, 16,917 deaths were caused
by overdoses involving prescription opioids. The number of overdose
deaths jumped to 33,000 in 2015 with prescription opioid overdoses
contributing to more than half the total. The death total then increased
again in 2016 to anywhere between 59,000-65,000 with prescription
opioids accounting for 40-50% of the death total. CDC Fifty-State Survey,
supra note 18; Understanding the Epidemic, CTR. DISEASE CONTROL &
PREVENTION, https://www.cdc.gov/drugoverdose/epidemic/index.html
(last updated Dec. 19, 2018).

30.

Prescription Opioid Data¸ CTR. DISEASE CONTROL & PREVENTION,
https://www.cdc.gov/drugoverdose/data/prescribing.html (last updated
Dec. 19, 2018); Understanding the Epidemic, supra note 29.

31.

Bhavani S. Reddy, The Epidemic of Unrelieved Chronic Pain: The
Ethical, Societal, and Regulatory Barriers Facing Opioid Prescribing
Physicians, 27 J. LEGAL MED. 427, 430 (2006).

32.

Section 1: Background and Significance, AM. PAIN SOC’Y,
http://americanpainsociety.org/uploads/education/section_1.pdf (last
visited Feb. 16, 2019).
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pain is defined as pain that continues beyond what was originally
thought to be the “expected healing time of an injury or illness.”33
Traditionally, severe pain that lasts for more than six months has been
categorized as “chronic.” Medical professionals have, however,
determined that a chronic pain diagnosis may be handed down as early
as two to four weeks from the initial onset of pain.34 An individual
coping with chronic pain may suffer from such severe and debilitating
pain that it takes a toll on the patient’s relationships and day-to-day
activities.35 If pain is left untreated, the individual may experience
depression, or loss of employment, spouse, family, and even a loss of life
if the patient commits suicide as a result of the chronic pain.36 In
contrast, when a patient’s pain is appropriately controlled and treated,
he or she is expected to experience an enhanced quality of life, increased
physical functionality, and an improvement in general overall health.37
Unfortunately, chronic pain is often undiagnosed and even when
diagnosed, it is generally undertreated.38
It is estimated that between forty-eight and fifty million Americans
suffer from chronic pain and that those individuals visit physicians’
offices approximately ninety million times a year seeking medical care
for their pain.39 As the population rises, the number of people who will
need treatment for chronic pain is expected to rise.40 Unfortunately for
those seeking palliative care,41 there is a significant public health
problem surrounding the undertreatment of pain.42 Despite the fact that
33.

Reddy, supra note 31, at 427.

34.

Id.; Gregory Minnis, What Is Back Pain?, HEALTHLINE (Jan. 16, 2019),
https://www.healthline.com/health/back-pain.

35.

Reddy, supra note 31, at 431.

36.

Id. at 432.

37.

Id.

38.

PAIN: CURRENT UNDERSTANDING OF ASSESSMENT, MANAGEMENT, AND
TREATMENTS, NATIONAL PHARMACEUTICAL COUNCIL at 3 (Dec. 2001),
available
at
http://americanpainsociety.org/uploads/education/
section_1.pdf.

39.

The number of chronic pain patients is expected to double by the year
2030 because people are expected to live longer. See Reddy, supra note
31, at 430; Beth Packman Weinman, Freedom from Pain, Establishing a
Constitutional Right to Pain Relief, 24 J. LEGAL MED. 495, 503 (2003).

40.

AM. PAIN SOC’Y, supra note 32, at 3.

41.

Palliative care is different than curative treatment. It is primarily aimed
at treating symptoms. See What are Palliative Care and Hospice Care?,
NAT’L INST. AGING, https://www.nia.nih.gov/health/what-are-palliativecare-and-hospice-care (last updated May 17, 2017).

42.

Oken, supra note 5, at 1931; Durning, supra note 11, at 215-19.
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physicians have the requisite knowledge and resources to manage pain
in an estimated ninety percent of individuals suffering from chronic
pain,43 it is estimated that more than forty to fifty percent of chronic
pain patients in routine practice settings fail to receive adequate pain
relief for their condition.44
The staggering numbers of undertreated patients may be attributed
to the failure to incorporate prescription opioids into chronic pain
treatment programs. In a recent survey, thirty-four percent of
physicians believe that moving away from powerful painkillers such as
opioids may be prolonging patients’ misery and harming those with
chronic pain issues.45 Despite the negative implications raised by the
opioid crisis, opioids and other pain-reducing medications still play an
important role in managing patient’s chronic pain.46 Prescribers often
view opioids as “the most effective, and often the only, treatment that
provides significant relief for most patients suffering from chronic
pain.”47 But, even though opioids have been essential for pain treatment
for thousands of years, and many medical professionals view
prescription opioids as a preferable, acceptable, and standard form of
treatment for chronic pain patients, opioids have proven to be grossly
underutilized in chronic pain management.48
Failure to manage a patient’s pain creates harmful consequences
and causes significant suffering.49 Individuals with untreated pain may
suffer from serious mental complications, such as “anxiety, fear, anger,
[and] depression;” “impair[ed] recovery from injury or procedures;”50
and decreased quality of life, functionality, activity, appetite, and
productivity.51 Take the story of fifty-three-year-old Doug Hale, for

43.

AM. PAIN SOC’Y, supra note 32, at 3.

44.

Christine E Whitten et al., Treating Chronic Pain: New Knowledge, More
Choices, 9 PERMANENTE J. 9 (2005); Myra Glajchen, Chronic Pain:
Treatment Barriers and Strategies for Clinical Practice, 14 J. AM. BOARD
FAM. PRACTICE 211, 211 (2001).

45.

Happening Now: Are Doctors Harming Patients by Cutting Back on
Prescription
Painkillers?,
FOX
NEWS,
(Jan.
6,
2017),
https://www.foxnews.com/ health/happening-now-are-doctors-harmingpatients-by-cutting-back-on-prescription-painkillers.

46.

Gatchel, supra note 13.

47.

Durning, supra note 11, at 221; Reddy, supra note 31, at 428.

48.

Reddy, supra note 31, at 428.

49.

AM. PAIN SOC’Y, supra note 32, at 3.

50.

Id.; see Reddy, supra note 31, at 430.

51.

See Reddy, supra note 31, at 431.
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example.52 Mr. Hale suffered from interstitial cystitis, severe migraines,
and a back condition.53 He was prescribed methadone and oxycodone in
2001 and continued to take the medication until his untimely death.54
During his treatment, Mr. Hale’s physician eventually told Mr. Hale
that he did not want to risk his medical license and, therefore, he could
no longer provide Mr. Hale with his pain medication.55 Mr. Hale suffered
for six weeks while attempting to find another doctor to treat his pain
– those six weeks without pain medication drove Mr. Hale to suicide.56
Similarly, Hailey Weeks met an untimely death due to a lack of
chronic pain treatment. Ms. Weeks injured her back at age thirty-five
and never recovered.57 She received opioids and sedatives to help with
the pain, but when her doctor retired, she was left “with a one-month
prescription and a list of doctors” to call.58 When those doctors refused
to treat her, Ms. Weeks decided to try to wean herself off the
medication.59 As a result, Ms. Weeks hastened her alcohol abuse, which
lead to a trip to the emergency room, and then found herself in jail,
where she eventually died.60
Lastly, consider the story of Jean Karchefsky – a sixty-three-yearold retired school bus driver.61 Ms. Karchefsky’s doctor told her that he
would no longer treat her longstanding chronic pain resulting from disk
and bone degeneration in her neck and spine.62 Unable to find a new
doctor willing to renew her prescription, Ms. Karchefsky has suffered
for months, going through withdrawal and with pain that leaves her
vulnerable to nausea, anxiety, and insomnia.63
52.

Stefan Kertesz & Sally Satel, Some People Still Need Opioids, SLATE
(Aug. 17, 2017, 3:53 PM), https://slate.com/technology/2017/08/
cutting-down-on-opioids-has-made-life-miserable-for-chronic-painpatients.html.

53.

Id.

54.

Id.

55.

Id.

56.

Id.

57.

Id.

58.

Id.

59.

Id.

60.

Id.

61.

Brie Zeltner, Suffering and Abandoned: Chronic Pain Patients Cut Off in
the Opioid Era, CLEVELAND, https://www.cleveland.com/healthfit/
index.ssf/2018/04/suffering_and_abandoned_chroni.html (last updated
Oct. 19, 2018).

62.

Id.

63.

Id.
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In addition to psychological suffering, chronic pain may also prove
difficult for the patient to maintain employment and engage in what
most would consider daily activities.64 Difficulty maintaining
employment is unfortunately all too common for those who suffer from
unrelieved chronic pain. Chronic pain patients collectively use about
fifty million sick days per year, which renders chronic pain “the second
leading cause of medically related absenteeism and lost productivity in
the workplace.”65 Additionally, forty-two percent of those with chronic
pain report such severe pain that they are incapable of working.66 For
example, if an individual is a laborer, the physical limitations caused
by chronic pain may impair his or her ability to maintain employment.67
Even if the individual works a sedentary job, pain may impair his or
her concentration and make it difficult to complete necessary tasks.68
Simply sitting for a long period of time or tilting one’s head to view a
computer screen may become impossible due to chronic pain.69
In addition, some sixty-three percent of chronic pain patients are
unable to engage in the typical day-to-day activities that many healthy
individuals take for granted.70 The chronic pain sufferer is significantly
limited in his or her ability to carry out simple tasks like bathing,
dressing, eating, cooking, shopping, and doing the laundry.71 According

64.

Dennis Thompson Jr., Managing Chronic Pain at Work, EVERYDAY
HEALTH (Mar. 4, 2010), https://www.everydayhealth.com/painmanagement/managing-chronic-pain-at-work.aspx.

65.

Reddy, supra note 31, at 431.

66.

Weinman, supra note 39, at 505.

67.

WILLIAM SHAW ET AL., IMPROVING PAIN MANAGEMENT AND SUPPORT FOR
WORKERS WITH MUSCULOSKELETAL DISORDERS: POLICIES TO PREVENT
WORK DISABILITY AND JOB LOSS 3-7 (2017).

68.

Chronic Pain Has A Major Impact In The Workplace, C&S PATIENT
EDUC. FOUND. (Apr. 10, 2006), https://www.conquerchiari.org/
articles/pain-and-depression/effects-of/chronic-pain-has-a-major-impactin-the-workplace.html.

69.

Philip Kinghorn et al., Developing a Capability-Based Questionnaire for
Assessing Well-Being in Patients with Chronic Pain, 120 SOC. INDICATORS
RES. 897, 905, 911 (2015); see Kathleen Sutherland, When Chronic Pain
(Sept.
7,
2017),
Made
Me
Unable
to
Sit,
MIGHTY
https://themighty.com/2017/09/difficulties-sitting-chronic-painfibromyalgia/.

70.

Weinman, supra note 39, at 505.

71.

Paige Wyant, 16 Everyday Tasks, and What They Feel Like for a Person
With Chronic Pain, MIGHTY (Nov. 1, 2018), https://themighty.com/
2018/11/doing-basic-everyday-tasks-with-chronic-pain/#conversation.
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to studies, the inability to engage in daily living activities often leads
to increased frustration and depression.72
However, when a patient’s chronic pain managed and treated to
the fullest extent, he or she suffers less and can engage in average daily
activities, thereby experiencing greater quality of life.73 Unfortunately,
instead of ensuring that prescription opioids are accessible for those who
need them and inaccessible to those who do not, restrictive prescribing
legislation has hindered access to necessary treatments.
2.

Further Exacerbating Undertreatment – The Effects of the Opioid
Epidemic on the Chronic Pain Population

Despite potentially disastrous consequences, legislative and judicial
responses to the opioid epidemic have exacerbated the undertreatment
of chronic pain. The government’s “war on drugs” has instilled fear in
physicians which in turn has had a detrimental impact on the care they
provide to those suffering from chronic pain.74 There are now two more
barriers to accessing prescription opioids: (1) opiophobia; and (2) fear
of regulatory scrutiny.
a.

Infecting Prescribers With Opiophobia75

The first access barrier arises out of the fear that prescribing opioids
for long periods of time “creat[es] drug addicts.”76 Health care providers
have been infected with opiophobia.77 They fear that the use of narcotics

72.

Chronic
Pain
and
Depression,
AM. CHIROPRACTIC ASS’N,
https://www.acatoday.org/Patients/Health-Wellness-Information/
Chronic-Pain-and-Depression (last visited Feb. 2, 2018); Rachel Noble
Benner, Chronic Pain Not Only Hurts, It Also Causes Isolation and
Depression. But There’s Hope, WASH. POST (Jan. 12, 2015),
https://www.washingtonpost.com/national/health-science/chronic-painnot-only-hurts-it-also-causes-isolation-and-depression-but-thereshope/2015/01/12/db576178.

73.

Reddy, supra note 31, at 432.

74.

See Oken, supra note 5, at 1940.

75.

“Opiophobia refers to a phenomenon in which exaggerated concern about
the risks associated with opioids prevent appropriate medical use of opioid
analgesics. Anyone involved in the drug distribution system, as well as
patients, family members, and members of the public, can have these
exaggerated concerns.” Glossary – Opiophobia, PAIN & POL’Y STUDIES
GRP., http://www.painpolicy.wisc.edu/glossary/opiophobia (last visited
Apr. 10, 2019).

76.

See Reddy, supra note 31, at 428.

77.

See generally Dilcher, supra note 4, at 113-15.
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causes drug abuse and addiction, and are therefore reluctant to
prescribe, administer, or dispense controlled substances.78
Because chronic pain is typically treated with a long-term
prescription opioid regimen, a patient may build up tolerance and
physiological dependence and eventually need higher doses in order to
achieve adequate pain relief.79 Fear of “creating addicts” arises out of
the misperception that physical dependence is equivalent to addiction.80
But, it is important to realize that physiological dependence does not
always indicate addiction. Though addiction may occur as a result of
opioid pain treatment, physiological dependence and tolerance “is a
wholly distinct and separate phenomenon.”81 Physiological dependence
is defined as “the ability to use greatly increased amounts of a substance
with diminished intoxicating effect.”82 On the other hand, “[a]ddiction
is a behavioral disorder characterized by craving, drug use, and
continued use despite personal harm.”83 The behavioral patterns of an
addict tend to differ from that of an individual who is physiologically
dependent and the patterns of an addict can therefore be identified.
Those patterns include: (1) doctor-shopping; (2) repeated emergency
room visits wherein the individual requests opioid pain relievers; (3)
self-medicating by increasing the number of prescription medications
used; and (4) continually using a substance despite a decreased quality
of life.84
A chronic pain patient may exhibit the behavioral tendencies of an
addict if the patient is driven by untreated pain to display certain drugseeking behaviors.85 These individuals have been dubbed
“pseudoaddicts” but are actually chronic pain patients who have been
mistakenly diagnosed as addicts due to their behaviors.86 Regardless of
similar behaviors, pseudoaddicts are distinguishable from addicts
because they act only as a result of uncontrolled pain.87 To point out
the difference between the two: if an addict is given the drug that he
seeks, it only exacerbates his disease; but, if a pseudoaddict is given the
78.

Id. at 114.

79.

Reddy, supra note 31, at 436.

80.

Dilcher, supra note 4, at 115.

81.

Reddy, supra note 31, at 436.

82.

Id.

83.

Id. at 435.

84.

Id.

85.

Id. at 436.

86.

“Pseudoaddict” was coined in the late 1980s and carried through into the
1990s when the opioid epidemic began to take hold. See id. at 435-36.

87.

See id. at 437.
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medication he seeks, his physical functioning improves, he stabilizes,
and the behaviors that lead to him being categorized as a
“pseudoaddict” subside.88
Because referring to those with physiological dependence as addicts
stigmatizes patients, fuels opiophobia, and results in continued
undertreatment of chronic pain patients, it is important that when
passing future legislation, legislators are careful to differentiate between
the two in order to reduce the fear felt by providers.
b.

To Prescribe or Not to Prescribe – Intimidating Physicians Through
Threats of Regulatory Scrutiny

The second barrier to access is a direct result of restrictive drug
policies set forth by the legislatures: prescribers’ fear of regulatory
scrutiny.89 Physicians are faced with uncertainty about what constitutes
legitimate opioid prescribing practices and are further intimidated by a
regulatory system riddled with the threat of sanctions.90 The risk of
sanctions looms over physicians when deciding whether or not to write
an opioid prescription. Prescribers may face criminal prosecution, loss
of hospital privileges, and disciplinary action by medical licensing
boards.91 So, a prescriber, when asked why he or she is reluctant to
prescribe opioids to chronic pain patients, will likely respond that he or
she fears discipline for doing so.92 In fact, forty percent of the physician
members of the American Pain Society said just that when asked why
they avoided prescribing opioids for chronic pain. They stated “that
concerns about regulatory scrutiny, rather than medical considerations”
influenced their decision.93 In response to the increase in arrests,
prosecutions, and sanctions, doctors are changing their prescribing
practices to avoid attracting the unwarranted attention of state medical
boards.94 Physicians are now reducing the number of opioids prescribed
and the dosage provided, the number of refills available to patients, and
choosing drugs with a decreased potential for abuse.95 For example, a
2003 study concluded that the fear of addiction and side effects limited
88.

See id.

89.

See Weinman, supra note 39, at 532.

90.

Kelly K. Dineen & James M. DuBois, Between a Rock and a Hard Place:
Can Physicians Prescribe Opioids to Treat Pain Adequately While
Avoiding Legal Sanction? 42 AM. J.L. & MED. 7, 8 (2016); Durning, supra
note 11, at 215-16.

91.

Dineen & DuBois, supra note 90 at 7, 8.

92.

Weinman, supra note 39, at 532.

93.

Dilcher, supra note 4, at 85.

94.

Reddy, supra note 31, at 439.

95.

Id.
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prescribers’ usage of opioids to treat chronic pain. Specifically, the
study found that around half of the subjects had changed physicians at
least once because their doctor was unwilling to treat their chronic pain
with opioids.96 These self-protective measures may continue to further
negatively impact the treatment of chronic pain patients.97
Due to the already limited number of physicians willing to treat the
chronic pain population, increases in the arrests and prosecutions of
doctors have made it extremely difficult or nearly impossible for these
patients to seek care.98 The strict legislative approach taken in recent
years has instilled fear in prescribers who have since changed their
prescribing practices and reduced and/or eliminated the benefits that
chronic pain patients receive from opioid therapy.99 Reducing the
benefits provided to chronic pain patients by opioid medications is an
unsound approach to guarding against the conduct of those who wish
to use the medications illegally.100 Though the government needed to
act to combat the opioid epidemic, its solution was not as effective as
it could have been. It is time that the legislators focus on providing
access to those who are in need and restricting access to those who are
not. To narrow that focus and create tailored legislation, it is important
that legislators inform themselves about the basic building blocks of
medical decision-making: physician discretion and patient autonomy.
C.

Rights to Be Restored – Physician Discretion and Patient
Autonomy

The basis of medical decision-making rests in the patient-physician
relationship. That relationship is “one of mutual obligation,” which
means that a patient’s “autonomy must be balanced with respect for

96.

The study was conducted by the American Pain Society, the American
Academy of Pain, and Janssen Pharmaceutical. The study was conducted
by Roper Starch Worldwide. The sample was made up of 500,000
households which were representative of all households in the U.S., a total
of 35,000 screening questionnaires were sent to a random cross-section of
705 individuals. See Alexander DeLuca, The War on Drugs, the War on
Doctors, and the Pain Crisis in America – Eight Years of Naked
Emperors, DR. DELUCA (June 14, 2011), http://doctordeluca.com/
Library/WOD/WOD-PCA060404cWeb.htm.

97.

Dilcher, supra note 4, at 85; see Durning, supra note 11, at 217.

98.

Diane E. Hoffmann, Physicians Who Break the Law, 53 ST. LOUIS U. L.J.
1049, 1077 (2009).

99.

Durning, supra note 11, at 216-17.

100. Id. at 203-04.
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the physician’s autonomy.”101 Physician discretion is the right to
“discretionary latitude in clinical decisions.”102 Because society demands
that the physician make his knowledge available, society provides the
physician with sufficient discretionary latitude that allows him to
capably and safely apply that knowledge.103 Without this freedom, the
physician could not personalize individual care nor could he fulfill his
obligation to use his knowledge to benefit the patient.104
Despite the need for balance, patient autonomy dominates medical
decision-making in the United States.105 Patients have the right and
ability to make their own choices and decisions about medical care and
treatment they receive, however this right is not unrestricted. Once a
doctor provides a patient with a litany of treatment options, the patient
is free to make decisions about the treatment plan he or she would like
to pursue.106
Though there is widespread recognition for patient autonomy alone,
the patient-physician relationship cannot function without a healthy
respect for both patient autonomy and physician discretion.107
Unfortunately, laws surrounding opioid prescribing practices have
diminished physician discretion and patient autonomy by dictating
both the number of and how often opioids can be prescribed to a certain
individual and by imposing ever harsher sanctions on physicians who
break these new laws thereby causing them to fear prescribing opioids
at all. Though it is recognized that opioid prescribing practices need to
be regulated for safety purposes, a proper balance must be struck so as
to restore physician discretion and patient autonomy.108

II. The What and Why of Prescription Drug
Monitoring Programs
Legislative campaigns from the past twenty years have aimed at
combatting the opioid epidemic have been geared towards a closed101. Edmund D. Pellegrino, Patient and Physician Autonomy: Conflicting
Rights and Obligations in the Physician-Patient Relationship, 10 J.
CONTEMP. HEALTH L. & POL’Y 47, 51 (1994).
102. Id. at 61.
103. Id. at 52-53.
104. Id. at 61.
USLEGAL,
105. Right
to
Autonomy
and
Self
Determination,
https://healthcare.uslegal.com/patient-rights/right-to-autonomy-andself- determination/ (last visited Mar. 8, 2019).
106. Id.
107. Pellegrino, supra note 101, at 57.
108. See Oken, supra note 5, at 1943.
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regulation system with a “‘zero-tolerance’ approach.”109 These new laws
are jam-packed with burdensome administrative processes, ever-harsher
penalties, and more militant and expensive enforcement tactics.110 The
rigid nature of recent legislative enactments has placed a heavy burden
on both patients and prescribers.111 For example, strict limits on the
number of pills that can be dispensed at one time and limits on the
amount of time a patient is permitted to receive a specific medication
creates substantial obstacles for patients in remote areas or those who
have a disabling condition and cannot travel to collect their
prescriptions.112 Furthermore, due to recent legislation, physicians are
more reluctant than ever to prescribe opioids, not only because they
dread the trek through the newly created administrative maze, but also
because they fear prosecution for making a good faith mistake.113 The
new system will continue to limit patient access to prescription opioids
unless physicians feel comfortable prescribing and access is permitted,
encouraged, and facilitated by the government.114 It is clear that there
needs to be a balance between: (1) the freedom of physicians to use
their judgment in prescribing; (2) efficient processes by which
individuals in need of medication can receive it; and (3) legitimate law
enforcement efforts.115 Though the balance has yet to be struck, many
state governments took a step in the right direction by creating and
implementing prescription drug monitoring programs.
A.

What is a Prescription Drug Monitoring Program?

PDMPs are defined and function as “statewide electronic
database[s] which collect[] designated data on substances dispensed in

109. See Anderson & Davis, supra note 3, at 341; see also Oken, supra note 5,
at 1942.
110. Oken, supra note 5, at 1942; see also Anderson & Davis, supra note 3, at
340-41.
111. Oken, supra note 5, at 1942-43; see e.g., Anderson & Davis, supra note 3,
at 340-41.
112. See e.g., ALASKA STAT. § 08.36.355 (2019); H.B. 333, 2017 Gen. Assemb.,
Reg. Sess. (Ky. 2017); N.J. ADMIN. CODE § 13:45H-7.5-7.20 (2019); Act
122, 2016 Gen. Assemb., Reg. Sess. (Pa. 2016); Act 125, 2016 Gen.
Assemb., Reg. Sess. (Pa. 2016); Anderson & Davis, supra note 3, at 358.
113. Anderson & Davis, supra note 3, at 359.
114. Id.
115. See generally Oken, supra note 5, at 1942-43; See also Jeffrey A. Singer,
In the Opioid Crisis, Keep Your Eyes On Heroin and Fentanyl, CATO
INST., (Oct. 25, 2017), https://www.cato.org/publications/commentary/
opioid-crisis-keep-eyes-heroin-fentanyl.
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the state.”116 These programs contain and compile information on
controlled substance prescriptions written by prescribers and dispensed
by pharmacies.117 PDMPs collect data via prescribers and pharmacists
entering controlled substance prescriptions into the centralized
database thereby making the information available to authorized
users.118 Authorized users typically include prescribers and pharmacists,
as well as licensure boards, law enforcement, medical examiners, drug
courts, criminal diversion programs, addiction treatment programs,
insurance companies, and other public health and safety agencies.119
The extent of access varies among users, but it is clear that only
authorized users can access the data and those users can only access
the data with login credentials provided by registering with the
requisite state prescription drug monitoring program.120 Once
authorized, users can see data including the name of the patient,
prescriber, pharmacy, prescription, dose, and form of payment.121
Armed with the information contained in the PDMP interface,
authorized users can use PDMP data to improve patient safety by
allowing prescribers to: (1) identify patients who are obtaining opioids
from multiple providers; (2) calculate the total amount of opioids
prescribed per patient per day; and (3) identify patients who are
prescribed substances that may increase the risk of abuse.122 Moreover,
the information collected by PDMPs may also be used to facilitate
access to prescription opioids for those in need; identify and prevent
drug abuse and diversion; and aid in identifying drug-addicted
individuals, thereby enabling intervention and treatment.123
116. State Prescription Drug Monitoring Programs – Questions and Answers,
DEP’T
OF
JUSTICE
&
DRUG
ENF’T
AGENCY,
U.S.
https://www.deadiversion.usdoj.gov/faq/rx_monitor.htm#4
(last
updated June 2016).
117. Finklea et al., supra note 29; What States Need to Know About PDMPs,
CTR. DISEASE CONTROL & PREVENTION, https://www.cdc.gov/
drugoverdose/pdmp/states.html (last visited Nov. 11, 2017).
118. See CDC Fifty-State Survey, supra note 18.
119. Steer & Gass, supra note 16, at 7.
120. Rebecca L. Haffajee, Preventing Opioid Misuse with Prescription Drug
Monitoring Programs: A Framework for Evaluating the Success of State
Public Health Laws, 67 HASTINGS L.J. 1621, 1634 (2016).
121. Steer & Gass, supra note 16, at 6-8.
122. See LISA N. SACCO ET AL., PRESCRIPTION DRUG MONITORING PROGRAMS,
CONGRESSIONAL RES. SERV. 4 (2018); Austin Frakt, A Helpful Tool to
Combat the Opioid Crisis, N.Y. TIMES (Sept. 11, 2017),
https://www.nytimes.com/2017/09/11/upshot/a-helpful-tool-to-combatthe-opioid-crisis.html; Haffajee, supra note 120, at 1634-35.
123. SACCO ET AL., supra note 122, at 3.
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A majority of states have operational PDMPs.124 As of recently,
legislation authorizing the collection of data is in place in every state
except Missouri.125 Despite the widespread creation and implementation
of PDMPS, each program varies in several important ways. First, state
PDMPs tend to differ with respect to the agency responsible for housing
and maintaining them.126 The agency charged with managing the
PDMP may be located in either the state’s Board of Pharmacy,
Department of Health and Human Services, or a law enforcement
agency.127 Second, states tend to take different stances on which
conditions need to be met in order for a user to be authorized to request
and receive PDMP reports.128 Lastly, though some states merely suggest
the use of PDMPS, other states mandate their use. For example, a state
may require prescribers to check the PDMP before writing a
prescription for an opioid.129 Overall, even though PDMPs vary widely
across the forty-nine states that have them, the principal goal of
effectively regulating controlled substances is generally accepted and
championed by each one.130

124. See Steer & Gass, supra note 16, at 5.
125. Id. at 7; Missouri does not have a functioning PDMP due to consistent
filibustering when legislation is introduced. Senator Rob Schaaf
consistently leads filibusters against any PDMP brought in front of the
Missouri legislature. Megan Thielking, Missouri is the Only State Not
Monitoring Prescription Drug Use. Will It Finally Create a Database?,
STAT NEWS (Mar. 7, 2017), https://www.statnews.com/2017/03/07/
missouri-prescription-drug- database.
126. Blumenthal & Seervai, supra note 28; Steer & Gass, supra note 16, at 7.
127. SACCO ET AL., supra note 122, at 4.
128. Id.; see also Prescription-Drug Monitoring Cuts Doctor-Shopping for
Painkillers, FOX NEWS (Feb. 17, 2017), http://www.foxnews.com/
health/2017/02/17/prescription-drug-monitoring-cuts-doctor-shoppingfor-painkillers.html.
129. See FOX NEWS, supra note 130. Kentucky, New York, and Ohio are
potential models for states looking to mandate prescriber use. See also
Mandated Use of State Prescription Drug Monitoring Programs (PMPs)
– Highlights of Key State Requirements, NAT’L ALLIANCE FOR MODEL
STATE DRUG L. (June 30, 2017), http://namsdl.dynamicwebware.com/
News%20Tab/Highlighted%20Issues/Mandated%20Use%20of%20State%
20Prescription%20Drug%20Monitoring%20Programs%20(PMPs)%20%20Highlights%20of%20Key%20State%20Requirements%20(June%2030
%2C%202017).pdf.
130. See Steer & Gass, supra note 16, at 8.
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B.

Why a Prescription Drug Monitoring Program?

The risks presented by prescription opioids make it clear that their
use needs to be monitored.131 But, combatting prescription opioid
diversion and abuse is no easy feat. An effective monitoring regime
requires the coordinated effort of various state regulatory, judicial, and
law enforcement bodies.132 To be clear, this Note recognizes that
PDMPs serve to supplement other state drug enforcement laws. But,
this Note focuses on the argument that, with a few changes, PDMPs
will address the issues surrounding prescription opioids.
Notwithstanding the need for other state laws, a top priority should be
that the program and accompanying guidelines enable health care
providers to rely on their judgment and confidently provide pain
treatments to those in need without fear of prosecution and criminal
discipline.133
C.

Current Regulatory and Legislative Problems

Aside from the laws that create PDMPs, other current state policies
restrict prescriber autonomy in three major ways.134 First, various state
policies place limitations on the ability to prescribe opioid pain
medications by preventing prescribing to patients with certain
characteristics. These policies focus on characteristics like age,
diagnosis, or prognosis.135 These restrictions tend to diminish a
prescriber’s ability to provide treatment to those in need and hinder
patient access to much needed pain treatment.136 For example, if a
physician treats a patient who under state law cannot receive an opioid
prescription for their pain, that physician is forced to seek out another
potentially less effective treatment method. Second, certain states
require prescribers to consult with at least one other provider before
writing a prescription for an opioid.137 Requiring a physician to present
his or her recommendations to another in order to write a prescription
deprives the doctor of his discretion and makes it more difficult for
131. Prescription opioids tend to be safe when taken as directed, but because
the drug interacts with pain receptors in the brain and nervous system
and produces a sense of euphoria in addition to pain relief, they can be
misused and abused. See generally COMMONWEALTH OF PA. & THE PA.
PHARMACISTS ASS’N, supra note 9; see also Steer & Gass, supra note 16.
132. Durning, supra note 11, at 241.
133. Id. at 215-16.
134. Dilcher, supra note 4, at 101-02.
135. Id. at 103.
136. Id.; see also Oken, supra note 5, at 1938-39; Trehan, supra note 4, at
962.
137. See Dilcher, supra note 4, at 103-04.
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chronic pain patients to receive the opioid pain medications they
need.138 Last, but most importantly, though federal law does not limit
the quantity of drugs that a prescriber can dispense, states are
beginning to limit the amount of opioid painkillers that can be
dispensed or prescribed at one time.139 States claim they are trying to
control the availability of prescription opioids that present a potential
for abuse and diversion, but state lawmakers need to understand the
real-life implications of their policies – hindering patient access to
needed pain relief treatment.140 For a chronic pain patient with a
disabling medical condition that renders it difficult for him to return to
the doctor multiple times to receive a new prescription and to travel to
a pharmacy to fill that prescription, may have to go days without
necessary medication.141 Patients without reliable transportation or
those who live in rural areas and have to travel long distances may
suffer the same fate.142
Opioids are safe and effective in the treatment and management of
pain but for them to be effective, they must be accessible.143 There needs
to be a substantially greater focus on palliative care when creating a
balanced policy approach relating to prescription opioids.144 Policies and
programs aimed at monitoring prescription opioids should crackdown
on unintended third parties and not on the intended recipients of
prescription opioids. Any response to the prescription opioid epidemic
that prevents patient access to medication and restricts prescribers’
abilities to manage pain could inappropriately further contribute to the
already rampant public health crisis of pain undertreatment.145 PDMPs
do the opposite; they assist prescribers and pharmacists in identifying
illict behavior while also ensuring that patients have access to the
medications they need.
D. The Benefits of PDMPs

Overall, PDMPs are taking promising steps to mitigate the opioid
epidemic.146 These data-collection programs continue to be among the
138. See id.
139. See id. at 100.
140. See Weinman, supra note 39, at 539; Dilcher, supra note 4, at 104-05.
141. Dilcher, supra note 4, at 105.
142. Id. at 104-05.
143. Id. at 82.
144. Id. at 109; Durning, supra note 11, at 239-40.
145. See Durning, supra note 11, at 241; see also Weinman, supra note 39, at
539.
146. See, e.g., Frakt, supra note 122, SACCO ET AL., supra note 122.
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most promising interventions aimed at combatting drug abuse and
diversion while ensuring that those in need of prescription opioid
painkillers have access.147 PDMPs allow prescribers and pharmacists to
identify, prevent, and deter drug abuse and diversion practices.148 When
a physician or other authorized user checks the database and sees an
unusual pattern of opioid distribution, they can deny or change a
prescription, screen for an opioid/substance abuse disorder, or even
counsel the patient and suggest seeking other forms of pain
management or addiction treatment if necessary.149
In 2012, a review article concluded that PDMPs, in general, are
responsible for reducing doctor-shopping150 and prescription drug
abuse.151 Statistics specifically show that in states with active PDMPs,
when investigating cases of doctor shopping, law enforcement officers
were able to solve cases significantly faster than in states without; and
while opioid abuse rates were increasing, the increase was slower in
states with PDMPs.152 Recent research funded by the National Institute
on Drug Abuse arrived at the same conclusion – PDMPs are effective
in reducing drug abuse, misuse, and curbing overdose deaths.153 After
reviewing the relevant statistics, researchers concluded that state

147. See, e.g., Frakt, supra note 122, SACCO ET AL., supra note 122; State
Successes,
CTR.
FOR
DISEASE
CONTROL
&
PREVENTION,
https://www.cdc.gov/drugoverdose/policy/successes.html (last visited
Nov. 11, 2017).
148. SACCO ET AL., supra note 122.
149. Frakt, supra note 122.
150. Doctor shopping occurs when a patient visits multiple providers to get
multiple prescriptions from each of them without the providers knowing
about the other prescriptions. Doctor Shopping Laws, CTR. FOR DISEASE
CONTROL& PREVENTION (2012), https://www.cdc.gov/phlp/docs/menushoppinglaws.pdf.
151. SACCO ET AL., supra note 122.
152. Id.
153. Overall, if a state implements a PDMP, there is likely to be a decrease of
1.12 opioid-related overdose deaths per 100,000 people annually. See
Prescription Drug Monitoring Programs Linked to Reductions in Opioid
Overdose Deaths, NAT’L INST. ON DRUG ABUSE (June 22, 2016),
https://www.drugabuse.gov/news-events/newsreleases/2016/06/prescription-drug-monitoring-programs-linked-toreductions-in-opioid-overdose-deaths.
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implementation of PDMPs was associated with an overall reduction in
opioid-related overdose deaths.154
By providing physicians with a medium through which they can
efficiently monitor a patient’s opioid use, while also paving the way for
physicians to safely continue to prescribe opioids, PDMPs have worked
to not only restore decisional autonomy to prescribers and ensure
efficacious access to prescription opioids for chronic pain patients, but
they have also taken steps that have proven successful in combatting
the opioid epidemic. PDMPs have finally struck the policy balance that
prescribers, patients, and lawmakers have been waiting for.
Unfortunately, despite the overarching success of PDMPs, the lack of
uniformity amongst the programs has led to problems that can only be
fixed by instating a uniform fifty-state PDMP. The uniform PDMP will
combat the challenges facing existing PDMPs by implementing new
strategies that result in greater collection and effective utilization of
data; greater interstate data sharing; and fewer unintended
consequences impacting access.

III. Problems Within Prescription Drug Monitoring
Programs and Their Solutions
A.

Problems with Current PDMPs

The significant differences among state PDMPs demonstrate the
lack of interstate communication and organization that unfortunately
surrounds many of the attempts to combat the opioid epidemic.155
Despite the fact that all forty-nine states with operational PDMPs
share many of the same goals, all forty-nine programs vary.156 The
154. The NIDA-funded research study found that state implemented PDMPs
that monitored greater numbers of drugs with high potential for abuse
and took care to more frequently update data had a larger decrease in
opioid-related overdose deaths than PDMPs that did not. Specifically,
states “that monitored four or more drug schedules and updated their
information at least weekly” had “1.55 fewer opioid-related overdose
deaths per 100,000” annually than other programs. See id.
155. See Haffajee, supra note 120, at 1625.
156. Prescription drug monitoring programs vary widely in ways such as: who
can see the data; whether unsolicited reports are sent to users; whether
prescribers/dispensers can delegate access to a certain person; whether a
patient has to be notified when and if their data is accessed; if data is
shared with other states; how frequently data is updated; and whether
training is required in order to become an authorized user. See Haffajee,
supra note 120, at 1636; SACCO ET AL., supra note 122; Prescription Drug
Monitoring Frequently Asked Questions (FAQ), PDMP ASSIST,
http://www.pdmpassist.org/content/prescription-drug-monitoringfrequently-asked-questions-faq (last visited Apr. 9, 2019).
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variations amongst the programs have led to four key issues that must
be addressed in order for PDMPs to continually succeed.157 These issues
are: (1) failure to collect sufficient data; (2) failure to effectively use
collected data; (3) failure to distribute data across state lines; and (4)
consequences of improperly structured PDMPs.
1.

Failure to Collect Sufficient Data

First, PDMPs, unfortunately, fail to collect enough data
successfully combat the opioid epidemic. Many state PDMPs do not
require prescribers or pharmacists to report vital information that could
assist in tracking down doctor-shoppers or those who engage in
prescription opioid diversion. For example, to evade detection, drug
abusers, doctor-shoppers, and prescription opioid diverters often pay
for prescription pain killers in cash rather than using their insurance
plan.158 It is important for states to track the method of payment used
by an individual picking up a prescription. Though there is an inherent
risk in failing to track cash transactions,159 a large percentage of states
do not require pharmacists to record the payment method that the
patient uses when picking up a prescription opioid.160 Most state
PDMPs also do not require pharmacists to record the name or identity
of the individual picking up the prescription opioid.161 In failing to
record the identity of the individual, these policies create a risk for
diversion. Lastly, as of 2014, state PDMPs failed to collect all relevant
prescriber data.162 State PDMPs fail to collect data relating to the
disciplinary history or whether a prescriber is even alive. 163 The lack of
data collection could allow a drug-seeking individual to fill an opioid
prescription: (1) written by a prescriber who is no longer permitted to
write prescriptions; or (2) written by an individual other than the
deceased prescriber on a deceased prescriber’s prescription pad. Fixing
this data gap would enable PDMPs to continue to allow access to those
in need of opioids while better serving the goal to prevent unintended
access.
157. See Hafaajee, supra note 120, at 1637, 1676.
158. Joanna Shepherd, Combating the Prescription Painkiller Epidemic: A
National Prescription Drug Reporting Program, 40 AM. J.L & MED. 85,
86 (2014).
159. To evade detection, drug abusers, doctor-shoppers, and prescription
opioid diverters often pay for prescription pain killers in cash rather than
using their insurance plan. Id.
160. Id. at 105.
161. Id.
162. Id. at 106.
163. Id.
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2.

Failure to Effectively Use the Data that is Collected

Authorized users with access to state PDMPs fail to properly enter
or use data that is collected. Specifically, many prescribers worry that
entering data into or checking the PDMP will prove to be burdensome
and become another task to complete in order to meet the requisite
“duty of care.” Prescribers fear that if this newly enhanced duty were
to be unmet, they would be subjected to sanctions and lawsuits.164
Though some states have tried to scare prescribers into using
prescription drug monitoring programs by threatening disciplinary
action for non-use, there is no universal “carrot and stick” approach
that has successfully raised the prescriber participation rate.165
As a result, at least eleven states are now requiring that prescribers
check PDMPs when writing a prescription for opioids for certain
patients and under particular circumstances.166 For example, a newly
enacted Pennsylvania law requires a prescriber to query the PDMP
system each time a patient is prescribed an opioid but does not require
a query if a patient is admitted to a licensed healthcare facility. Yet,
most states do not require prescribers and pharmacists to consult
PDMP data at all.167 However, suppose that a prescriber, regardless of
whether he is required to do so, does consult a PDMP. Often a new
issue arises – a failure to report timely data.168 Because prescribers and
pharmacists may only input data once every week or two, other
authorized users cannot see the most up-to-date or timely data. If a
prescriber or pharmacist does not have access to the most recent data,
they may be unaware of new information that indicates potential drug
abuse or doctor-shopping.169
3.

Failure to Distribute the Data Collected Across State Lines

Third, although a significant number of PDMPs are making efforts
to share data with other states, there are gaps in the uniformity,
efficacy, and real-time sharing of data across state lines.170

164. See id.
165. See id. at 86.
166. Haffajee, supra note 120, at 1636 n.86.
167. Kelly K. Dineen, Addressing Prescription Opioid Abuse Concerns in
Context: Synchronizing Policy Solutions to Multiple Complex Public
Health Problems, 40 L. & PSYCHOL. REV. 1, 61 (2016).
168. Id. at 62.
169. See What States Need to Know About PDMPs, CTR. FOR DISEASE
CONTROL & PREVENTION (Oct. 3, 2017), https://www.cdc.gov/
drugoverdose/pdmp/states.html.
170. Shepherd, supra note 158, at 107.
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Implementing full interstate data-sharing measures will involve making
extensive changes to existing programs and require coordination among
many regulatory and legislative bodies, which is a major challenge for
new data-sharing initiatives.171 Unfortunately, some states have not
enacted legislation that provides the authority to share this type of
data.172 The federal government tried to jumpstart interstate data
sharing by creating the Prescription Monitoring Information Exchange
(“PMIX”). PMIX is a system intended to promote and enable
interoperability between state PDMPs.173 The system provides
information on an individual’s prescription drug history by establishing
RxCheck Hubs.174 Hubs can exist at either the national or state level
and information can be shared amongst all hubs.175 For privacy
purposes, patient data is encrypted as it passes through the hubs and
no data is actually stored on the hub.176 But instead of joining PMIX,
forty-one states became members of PMP InterConnect which
facilitates the transfer of PDMP data between participating states.177
Though this is a step in the right direction, eight states still fail to share
their data with the rest of the country which may provide an incentive
for drug abusers and diverters to cross state lines to obtain prescription
opioids.
4.

The Consequence of Improperly Structured PDMPs

Lastly, if improperly tailored or structured, PDMPs may have an
unintended consequence.178 Though PDMPs typically strike the proper
balance between physician discretion, patient access, and efforts to
combat the opioid epidemic, prescribers may still refuse or hesitate to
prescribe opioids that are monitored by the PDMP due to the extra
171. Id.
172. Id.
173. Prescription Monitoring Information Exchange (PMIX) Architecture,
PRESCRIPTION DRUG MONITORING PROGRAM TRAINING & TECHNICAL
ASSISTANCE CTR., http://pdmpassist.org/content/prescription-drugmonitoring-information-architecture-pmix (last visited Mar. 16, 2018).
174. Id.
175. Id.
176. PMIX National Architecture Overview, PRESCRIPTION DRUG MONITORING
PROGRAM
TRAINING
&
TECHNICAL
ASSISTANCE
CTR.,
https://www.pdmpassist.org/pdf/PMIX%20National%20Architecture%2
0Overview.pdf (last visited Feb. 17, 2019).
177. NABP PMP InterConnect: The Only National Network of State-Based
PMPs, NAT’L ASS’N BOARDS PHARMACY, https://nabp.pharmacy/
initiatives/pmp-interconnect/ (last visited Jan. 9, 2019).
178. SACCO ET AL., supra note 122.
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scrutiny by law enforcement.179 These increasing concerns may further
contribute to the crisis of undertreatment that PDMPs were designed
to alleviate. In addition, some patients may also fear scrutiny from law
enforcement authorities for using prescription opioids monitored by the
PDMP, even if they have a legitimate medical reason for doing so.180
B.

How a Uniform Approach Can Fix the Problems that Exist Within
Current State PDMPs

Many of the problems that relate to PDMPs arise out of a lack of
regulatory and legislative uniformity. The best way to address
contemporary challenges is to give states the option to adopt a new,
comprehensive, and uniform PDMP laws that quell patient and
prescriber concerns by restoring autonomy to both parties while also
bringing down the “legislative hammer” on those who contribute to the
opioid epidemic.
1.

State Licensing Boards, New Reporting Requirements, and the
Solution to Inadequate Data Collection

To improve data collection, the uniform PDMP will require that
prescribers and pharmacists include more information in the reports
they submit. Though entering more information into the PDMP
interface may place a burden on prescribers and pharmacists, increasing
the amount of available information will assist them in identifying
doctor-shoppers and individuals who divert prescription opioids.181
As it pertains to prescribers, the uniform PDMP will adopt the
information reporting requirements of Indiana’s PDMP, INSPECT.182
The uniform PDMP, like INSPECT, will require that, whenever a
controlled substance is prescribed, the prescriber reports: (1) the
recipient’s name and date of birth; (2) the national drug code number;183
(3) the date the prescription was written; (4) the quantity and number
of days of supply of the opioid given; (5) the prescriber’s Drug
Enforcement Administration (DEA) registration number; and (6)
whether the prescriber transmitted the prescription to the pharmacy
orally or in writing.184
179. Id.
180. Id.
181. See Shepherd, supra note 158, at 106, 108.
182. See generally IND. CODE § 35-48-7 (2017) (repealed and amended by 2010
Ind. Leg. Serv. 84 (West)).
183. National
Drug
Code
Directory,
FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/informationondrugs/ucm142438.htm
(last
visited Feb. 9, 2019).
184. IND. CODE § 35-48-7-8.1 (2018).
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As it pertains to pharmacists, the uniform PDMP will adopt the
reporting requirements currently used by the Washington and Alabama
PDMPs.185 Before an opioid is dispensed, the uniform PDMP will
require pharmacists to report: (1) patient identifiers including their
name, social security number, and date of birth; (2) the name of the
drug dispensed; (3) the date the drug is dispensed; (4) the quantity of
the drug dispensed; (5) the prescriber’s name; (6) the dispenser’s name
and location;186 and (7) the method of payment used.187 Adopting these
reporting requirements resolves an issue that surrounds current PDMPs
– specifically, the failure to record the identity and method of payment
used by the individual picking up the prescription. Requiring the
pharmacist to record a patient identifier and the method of payment
will decrease possible opportunities for diversion and assist in
identifying individuals who engage in those practices.
Adopting elements from existing PDMPs is a step in the right
direction, but it does not completely solve the problem of inadequate
data collection. That is why the uniform PDMP must enter uncharted
territory and begin collecting data relating to the disciplinary or
life/death status of prescribers.188 To facilitate this data collection, the
uniform PDMP will be maintained by state professional licensing
agencies. The state licensing agency in charge of the uniform PDMP
will designate a group of people to form a board (“the Board”). State
licensing agencies should have discretion to decide the specific duties
that will be assigned to the Board and the qualifications Board members
should have. However, it is recommended that the Board be charged
with not only maintaining the PDMP, but also keeping prescriber data
up to date. Much like the data-entry timelines that apply to
pharmacists and prescribers, the Board should routinely update
prescriber statuses within the database.189 However, because prescriber
statuses are not likely to change as frequently as an individual’s
prescription, the board should be required to check and update
prescriber status once a month. By continually updating prescriber
information within the database, the uniform PDMP will take
significant steps toward preventing individuals from filling prescriptions
for opioids that are invalid because they are written by a prescriber
185. See generally WASH. REV. CODE § 70.225 (2018); see also H.B. 150,
2013 Gen. Assemb., Reg. Sess. (Ala. 2013).
186. Prescription Monitoring Program, WASH. REV. CODE § 70.225.020(2)
(2018).
187. H.B. 150, 2013 Gen. Assemb., Reg. Sess. (Ala. 2013).
188. See Shepherd, supra note 158, at 106, 111.
189. See 14-118-11 ME. CODE. R. § 5(C)(1) (LexisNexis 2017); OR. ADMIN. R.
410-121-4010(1) (2019).
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who is no longer licensed or by an individual using a deceased
prescriber’s prescription pad.190
2.

Curing the Ineffective Utilization of PDMP Data by Facilitating
Access, Enrollment, and Consultation

Addressing the ineffective utilization of PDMP data is more
difficult than addressing the issue of data collection, but it can be done
by: (1) providing simple online access and increasing prescriber and
pharmacist participation by increasing the availability of educational
and promotional campaigns; (2) mandating prescriber use; (3) allowing
prescribers to designate someone on staff to access the PDMP on their
behalf; and (4) issuing automated reports.191
a.

Expediting Enrollment and Mandating Agency-Sponsored Training
Programs

First, many prescribers and pharmacists attribute their lack of
PDMP consultation to burdensome enrollment and difficulties
associated with use.192 For example: in some states individuals that
register for the PDMP must also look through an extensive list of
practices and register individually for each practice applicable to
them.193 This process could take hours and may dissuade prescribers
and pharmacists from registering with the PDMP. Moreover, after
gaining access, many physicians argue that it takes a considerable
amount of time to navigate the online portal and therefore do not use
it.194
To facilitate prescriber use, the uniform PDMP will first provide a
streamlined enrollment process that will institute automatic PDMP
registration. This automatic registration will be triggered by DEA
controlled substance registration.195 Massachusetts has the MassPAT
system, which automatically enrolls DEA registrants.196 Following this
program, the uniform PDMP will issue registration to any physician,
dentist, or podiatrist, who is duly authorized to practice in the state
and is registered with the DEA to prescribe or dispense prescription
190. See Shepherd, supra note 158, at 111.
191. SACCO ET AL., supra note 122; see also State Prescription Drug Monitoring
Programs– Questions and Answers, supra note 116.
192. See Marilyn Bulloch, The Evolution of the PDMP, PHARMACY TIMES (July
25,
2018),
https://www.pharmacytimes.com/contributor/marilynbulloch-pharmd-bcps/2018/07/the-evolution-of-the-pdmp.
193. See generally 105 MASS. CODE REGS. § 700.004 (2019).
194. SACCO ET AL., supra note 122.
195. See 105 MASS. CODE REGS. § 700.004(D) (2019).
196. Id.
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opioids.197 By automatically enrolling DEA registrants, the uniform
PDMP will shift the burden of enrollment to the state licensing agency
that manages the uniform PDMP.
The uniform PDMP will also require the Board to provide training
on how to access and use PDMP data.198 First, the Board should
contract with the vendor who provides the interface in order to obtain
and design an online technical assistance program.199 At a minimum,
the program should include tutorials on: how to access prescription
monitoring information; rights of persons whose information the user is
viewing; responsibilities of persons who access PDMP information;
permitted uses of PDMP information; and possible penalties for failure
to use or improper use by authorized users.200 The online system will
then be offered to registered PDMP users.201 Authorized users must
successfully complete the training program before having access to the
system.202 The Board should also be responsible for engaging with the
vendor on a regular basis to provide new tutorials as needed; keeping
the online technical assistance program up-to-date and informing
authorized users of the new tutorials. For example, if a new feature was
added to the uniform PDMP, the Board should be responsible for
contacting the vendor, specifying the new tutorial that is needed, and
informing all of the authorized users in the state about that new
tutorial. Once an authorized user is informed of a new tutorial, that
user must successfully complete the tutorial within six months.203
By expediting the enrollment process through automatic
registration and mandated agency-sponsored training programs,
prescribers and pharmacists will be more likely to competently comply
with the requirements of the uniform PDMP.
b.

Mandating PDMP Consultation

Taking steps to facilitate enrollment and use are not enough. The
best way to ensure that prescribers and pharmacists consult the PDMP

197. See id.
198. See e.g., 105 MASS. CODE REGS. § 700.004(F)(2) (2019); N.J. STAT. ANN.
§ 45:1-46(26)(k) (West 2018); MINN. STAT. § 152.126(2)(b) (2019).
199. MINN. STAT. § 152.126(2)(b) (2019).
200. See N.J. STAT. ANN. § 45:1-46(26)(k) (West 2019).
201. See id.
202. See 105 MASS. CODE REGS. § 700.004(F)(2) (2019).
203. Based off the idea adopted by Massachusetts lawmakers that authorized
users must successfully complete a training program that meets the
specifications sets by the agency that maintains the PDMP every two
years. See e.g., 105 MASS. CODE REGS. § 700.004(F)(2)(e) (2019).
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is to mandate it.204 Therefore the uniform PDMP, will require that
authorized users who dispense or prescribe opioids check the PDMP
before doing so. The uniform PDMP will require that dispensers, health
facilities, or individuals with DEA registration numbers both check the
system before prescribing and enter all prescribed or dispensed opioids
into the system. By issuing a comprehensive consultation mandate, the
uniform PDMP will ensure that most, if not all, pharmacies, drug
wholesalers, pharmacists, prescribers, and the like will check the
system, thereby cutting down illicit drug practices.205
c.

Reducing the Clinical Workflow Through Delegation

Because it is important that prescribers and pharmacists spend
more time with their patients or customers and less time consulting the
PDMP, in lieu of the mandate, the uniform PDMP will allow authorized
users to delegate the responsibility of checking the uniform PDMP to
other individuals such as RNs, LPNs, CRNAs, and pharmacy
technicians.206 However, there will be restrictions on whether or not an
individual can be a delegate. For example, an individual who is eligible
in his or her own right to become an authorized user may not serve as
a delegate under another authorized user.207 Furthermore, the
authorized user must submit a request to the Board asking it to create
a separate “delegate sub-account” for the authorized users.208 The Board
will have discretion to deny the authorized user’s request and may
thereby refuse to create a delegate sub-account.
If the Board grants access, delegates are considered “permissible
users” and are permitted to access the same data as authorized PDMP
users.209 To avoid improprieties and protect patient privacy concerns,
the uniform PDMP will set forth specific purposes for which authorized
users and their delegates may access PDMP data. To avoid penalties,
authorized and permissible users may only access PDMP data to the
extent that the information relates specifically to a current patient to
whom the prescriber is: (1) prescribing or considering prescribing a
controlled substance; (2) providing emergency medical treatment; (3)
204. White House Comm’n, supra note 25.
205. Studies show that the rate of doctor-shopping drops in states that require
pharmacists and prescribers to consult the PDMP prior to do dispensing
or prescribing opioids. See Frakt, supra note 122.
206. See e.g., H.B. 150, 2013 Gen. Assemb., Reg. Sess. (Ala. 2013); MINN.
STAT. § 152.126 (2019); see 14-118-11 ME. CODE. R. § 7 (LexisNexis 2017);
105 MASS. CODE REGS. § 700.004(I)(1) (2019).
207. See 105 MASS. CODE REGS. § 700.004(I)(1) (2019).
208. See generally 105 MASS. CODE REGS. § 700.004(I)(2) (2019).
209. See MINN. STAT. § 152.126(5) (2019).
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providing care to someone reasonably believed to have a substance
abuse problem; or (4) there is a clinically valid reason for checking the
system. 210
Delegation will make it easier for authorized users to work PDMP
consultation into their everyday clinical duties. Prescribers will be able
to spend more time with patients and will be less likely to argue that
mandated PDMP consultation constitutes a significant burden.
d.

Board Issued Reports

To further ensure that PDMP data is utilized in the most effective
way the Board will determine whether or not to issue a report indicating
that there are concerns regarding a patient seeking or receiving
opioids.211 The Board shall have discretion to determine the way by
which patients are flagged in the system, thereby indicating that a
report may need to be issued. For example, the Board may hire
individuals to review entries, or more efficiently, invest in software that
reviews each entry and alerts the Board when there is an issue. Once
disseminated to providers and pharmacies, the report will instruct
authorized users to log into their accounts to view the patient’s
prescription history.212 When viewing the report, the authorized user
will see: the names of the providers and pharmacies that prescribed or
dispensed opioids to the patient; the name and quantity of the drug
prescribed or dispensed; and other prescriptions that the patient was
prescribed in the last three months.213 Though it may strike some as a
violation of the patient’s privacy, the report is only available to
authorized users, and not law enforcement. The report is issued to
encourage authorized users to talk to their patients about possible
treatment for abuse and misuse while also taking proactive steps toward
preventing further illicit behavior.
When considering whether to disseminate a report, the Board
should consider whether the behavior exhibited by the patient is
indicative of: (1) abuse, misuse, or diversion of a controlled substance;
or (2) doctor-shopping.214 If the Board notices that an individual
receives an excessive amount of prescriptions containing opioids,
210. See 105 MASS. CODE REGS. § 700.004(C)(2) (2019).
211. See e.g., N.J. STAT. ANN. § 45:1-46(26) (West 2019); see also Guidance
on PDMP Best Practices: Options for Unsolicited Reporting, PDMP CTR.
EXCELLENCE BRANDEIS UNIV. (May 2016), http://www.pdmpassist.org/
pdf/COE_documents/Add_to_TTAC/Update%20to%20Brandeis%20C
OE%20Guidance%20on%20Unsolicited%20Reporting%20final.pdf
[hereinafter Options for Unsolicited Reporting].
212. Options for Unsolicited Reporting, supra note 211.
213. See id.
214. N.J. STAT. ANN. § 45:1-46(26) (West 2019).
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receives prescriptions from a variety of prescribers, or visits a large
number of pharmacies in a certain period, it may issue a report.215
By facilitating enrollment and use through automated registration
and educational programs, mandating PDMP use while also helping to
balance clinical workflow by allowing users to delegate PDMP
consultation, and sending automated reports, the uniform PDMP will
ensure that prescribers and pharmacists alike are effectively utilizing
this data resource.
3.

Conforming to the National Prescription Monitoring Information
Exchange Architecture

As of September 2017, forty-three states permitted PDMP
interstate data-sharing on some level.216 But, due to a lack of
uniformity, there is still insufficient access to all available PDMP
data.217 To improve existing PDMPs, the uniform PDMP will require
states to conform with PMIX to increase data sharing among states.218
In order to participate in PMIX, states must: (1) have legislation
allowing them to share patient information with authorized users in
other states in real time; (2) identify at least one other state with which
it desires to partner to exchange data; and (3) either establish a
memorandum of understanding with its identified partner(s) or ratify
the prescription monitoring interstate compact (“PMIC”).219 PMIC is
an “agreement between two or more states for cooperative effort,
mutual assistance, management, and regulation of [prescription opioid
prescriptions] by the states, which transcend the boundaries of one
state.”220 Moreover, any provisions within PMIC take precedence over
conflicting and inconsistent laws of states.221
If a state adopts the uniform PDMP, that state will have to adopt
legislation that allows patient information to be shared with authorized
users in other states in real time. The uniform PDMP will require states
to share patient information with all other states who adopt the uniform
PDMP by requiring states to join PMP InterConnect if they have not
215. Options for Unsolicited Reporting, supra note 211.
216. SACCO ET AL., supra note 122.
217. PDMPS AND THIRD PARTY PLAYERS MEETING, REPORT OF PROCEEDINGS,
BUREAU OF JUSTICE ASSISTANCE U.S. DEP’T JUSTICE (Apr. 2014).
218. See SACCO ET AL., supra note 122; Frakt, supra note 122.
219. Id.
220. R. Crady deGolian, Prescription Monitoring Program Compact, NAT’L
CTR.
STATE
GOVERNMENTS,
http://www.csg.org/programs/
policyprograms/NCIC/documents/PMPBackgrounder.pdf (last visited
Mar. 16, 2018).
221. Id.

496

Health Matrix·Volume 29·Issue 1·2019
50 Shades of Data Sharing: How a Uniform Fifty-State Prescription Drug
Monitoring Program Can Restore Discretion to Opioid Prescribers and
Autonomy to Chronic Pain Patients

already. By taking these steps, states will take significant steps toward
successful interstate data-sharing.
4.

Counteracting Unintended Consequences

Another issue facing the uniform PDMP is whether and how to
allow law enforcement access. A majority of states, for obvious reasons,
allow pharmacists and prescribers to access PDMP information related
to their patients.222 But some states also allow other entities such as law
enforcement to access the information.223 Prescribers typically object to
PDMPs that permit this type of access because they see these programs
as placing law enforcement above healthcare and patient treatment.224
Their fear is not unwarranted. If law enforcement and licensing agencies
have access to PDMP files without presenting probable cause or
overcoming reasonable restrictions, PDMPs could turn into instruments
used to sniff out criminal conduct and not be embraced by the medical
community.225
To ensure that prescribers are entitled to use their best judgment
in creating treatment plans for patients in need, the uniform PDMP
will adopt an approach similar to that of the Oregon PDMP.226 The
uniform PDMP will require that any federal, state, or local law
enforcement agency that wishes to have access to PDMP data be
engaged in an authorized drug-related investigation of a specific
individual.227 The uniform PDMP will require that the law enforcement
agency submit a request form that specifies the information requested
and a copy of a valid court order based on probable cause.228 Once the
agency submits the form, it is up to the Board to review the request
and determine whether or not to provide the agency with the requisite
information. 229
Allowing the Board to review law enforcement requests will strike
the proper balance between facilitating drug investigations and
222. Haffejee, supra note 120, at 1634; NAT’L ALL. FOR MODEL STATE DRUG
LAWS, STATES THAT ALLOW PRESCRIBERS AND/OR DISPENSERS TO
APPOINT A DELEGATE TO ACCESS TO PMP (2014).
223. Haffejee, supra note 120, at 1634.
224. See Andis Robeznieks, PDMP Case Pits Patient Privacy Against LawEnforcement Intrusion, AM. MED. ASS’N (Aug. 16, 2017),
https://www.ama-assn.org/delivering-care/patient-supportadvocacy/pdmp-case-pits-patient-privacy-against-law-enforcement.
225. Haffejee, supra note 120, at 1657.
226. See generally OR. ADMIN. R. 410-121-4020(35) (2019).
227. Id.
228. OR. ADMIN. R. 410-121-4020(36) (2019).
229. Id.
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protecting doctor/patient autonomy and permit PDMP goals to remain
intact.230
5.

Additional Measures to Bolster the Effectiveness of the Uniform
PDMP

Aside from the issues that commonly plague PDMPs, there are
additional improvements that can be made. In addition to the
previously mentioned policy changes, the uniform PDMP will expand
the number of drug schedules monitored by the program.231 Drugs and
the substances or other chemicals used to make them are placed into
one of five schedules. The drug, substance, or chemical is classified into
a certain schedule after the drug’s acceptable medical uses, and
potential for abuse or dependency are analyzed.232 Lower numbered
schedules are associated with a higher risk drug, for example, schedule
one drugs are illegal and have no accepted medical uses.233 Opioids tend
to fall within schedules two and four,234 therefore because studies show
that the more schedules monitored by a state PDMP, the lower the
rate of opioid-related overdose deaths, the uniform PDMP will require
that states also monitor drugs that fall within schedules two through
five. This means that the uniform PDMP will monitor all drugs with
accepted medical uses that are subject to potential abuse.235
The uniform PDMP will also require authorized users, primarily
prescribers and pharmacists, to input data more frequently. But, to
minimize any potential burden, prescribers and pharmacists will be
required to upload information into the database at set, daily
intervals.236 It is important that these users upload data no later than
230. See Haffajee, supra note 120, at 1662.
231. See Prescription Drug Monitoring Programs Linked to Reductions in
Opioid Overdose Deaths, supra note 153; see also, 105 MASS. CODE REGS.
§ 700.004(G)(1) (2018).
232. Drug Schedules, U.S. DRUG ENF’T ADMIN., https://www.dea.gov/drugscheduling (last visited Mar. 16, 2018).
233. Id.
234. Id.
235. Prescription Drug Monitoring Programs, CONG. RESEARCH SERV. (May
24, 2018), https://www.everycrsreport.com/reports/R42593.html; see
e.g., H.B. 150, 2013 Gen. Assemb., Reg. Sess. (Ala. 2013); 105 MASS.
CODE REGS. § 700.004(G)(1) (2018); see USING THE PDMP TO OPTIMIZE
PAIN MANAGEMENT, PA. PRESCRIPTION DRUG MONITORING PROGRAM
SYSTEM USER AND STAKEHOLDER TRAINING (2017), available at
https://www.health.pa.gov/topics/Documents/Programs/PDMP/3PDMP_UsingPMDP-Guide_F.pdf.
236. See e.g., 902 KY. ADMIN. REGS. 55:110 § 2 (2019); See also 14-118-11 ME.
CODE. R. § 5(C)(1) (LexisNexis 2017).
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midnight on the day on which the prescription was written and the day
it was filled, because these users are responsible for supplying the
uniform PDMP with essential data. However, these users may file for
an extension if needed. Users responsible for inputting data may file for
an extension within twenty-four hours after discovering either: (1) a
mechanical or electrical failure; or (2) a reason beyond the user’s control
that prevents the user from inputting data on time.237 The user must
submit the extension request to the Board who should then issue a
response within twenty-four hours. If the request falls within either of
the above stated categories, the Board should grant the extension and
the user will be free from penalties. But, if the Board denies the
extension, absent the user self-reporting the necessary data, the user
will be subject to penalties for failing to upload PDMP data in a timely
manner.238
By making additional modifications, the uniform PDMP will
protect the autonomy of chronic pain patients, the discretion of doctors,
and may even save the lives of opioid abusers. However, the
improvement should not end here. The uniform PDMP should operate
with as much flexibility as possible – allowing it to change as required
to serve its purpose in combatting the opioid epidemic as well as the
chronic pain population. The Board should remain vigilant in
monitoring opioid-related statistics and make changes to the program
as needed to ensure that the system achieves its overall goals.
6.

How Does This Fix the Problem?

There are numerous issues that contribute to the undertreatment
of pain in the United States, however two of the most serious obstacles
to proper pain management are legal and societal.239 Restrictive laws,
regulations, and guidelines surrounding prescription opioids have led to
confusion about the appropriate role of opioids in pain management
and put pressure on physicians to constrain prescribing.240 As a result,
many physicians, out of fear of fueling the ever-worsening epidemic,
began asking chronic pain patients who receive opioids to sign “pain
contracts.”241 If a patient signs this contract, he is agreeing to only
obtain medication from one doctor, submit to random drug screens and
pill counts, and not to engage in any criminal activity which may
include, but is not limited to using heroin or selling prescription
237. See 902 KY. ADMIN. REGS. 55:110 § 2(4)(a) (2019).
238. Penalties for failure to comply with reporting
requirements are to be left to the Board’s discretion.
239. AM. PAIN SOC’Y, supra note 32, at 17.
240. Id. at 17.
241. Zeltner, supra note 61.
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drugs.242 There is little evidence that the contracts work to deter
prescription drug diversion, however they do work to further restrict
legitimate access. However, the uniform PDMP provides a method by
which to reduce these issues. The PDMP can be used to solve the
continuing undertreatment problem by reducing the need for
burdensome and restrictive government action while ensuring that
those who need prescription opioids actually receive them.243
The uniform PDMP will first reassure physicians that opioids have
a legitimate place in the realm of pain management. The uniform
PDMP will provide an efficient method by which physicians can
effectively manage, improve, and change pain management strategies.
In doing so, the uniform PDMP will guarantee that chronic pain
patients are receiving the medications they need while also facilitating
discussions about alternative pain management. The uniform PDMP
can also assist physicians in developing a patient’s medical history
which in turn supports patient safety.244 Because the PDMP will serve
as an interface for opioid prescription data, a physician will have access
to a patient’s previous prescriptions and be able to determine whether
the patient needs an increased or decreased dosage, or whether the
patient may need to seek help if they are exhibiting dangerous or
addictive tendencies. Similarly, because the PDMP serves as a
monitorable interface, physicians will be able to readily identify drugseeking behavior and thereby reduce doctor-shopping, diversion of
controlled substances, and assist in other elements used to curb the
abuse of prescription opioids, thereby eliminating the need for
restrictive legislation, regulation, and guidelines that serve to harm the
chronic pain population.

IV. Conclusion
Beginning in the 1990s, the United States has fallen victim to the
opioid epidemic. Since then, state legislatures have searched for a
comprehensive solution.245 However, state actions have failed to strike
the necessary balance. Recent judicial, regulatory, and legislative steps
created an overtly restrictive regime that impeded physician discretion
and patient autonomy.246 It seems as though legislators failed to
consider the importance of medical decision-making when trying to
create a comprehensive approach to battling the opioid epidemic.
242. Id.
243. Id.
244. Id.
245. Reddy, supra note 31, at 439.
246. See Weinman, supra note 39, at 531-533.
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Moreover, recent legislative approaches have prevented chronic pain
patients accessing much needed opioid prescriptions.247 In addition to
already existing public health crisis related to the undertreatment of
pain, restrictive state approaches added additional hurdles for these
patients to access prescription opioids.
However, many states took a step in the right direction by
implementing PDMPs. In doing so, states provided prescribers and
pharmacists with useful tools to detect abuse, misuse, drug diversion,
and other illicit drug practices. However, these programs lacked
uniformity and were riddled with issues such as inadequate data
collection, ineffective utilization of data, insufficient interstate datasharing, and other unintended consequences. Therefore, despite taking
an initial step in the right direction, state action has halted until a
solution is implemented.
Fortunately, a solution can be found by means of a uniform PDMP.
The uniform PDMP will build upon current state PDMPs by using
promising practices. The new system will ensure that data is used
effectively and efficiently by prescribers and pharmacists while quelling
physicians’ sanction-related fears. If states adopt the uniform PDMP
and use it in conjunction with other less-restrictive measures adopted
to combat the epidemic, the entire regime will equate to a promising
step toward combating, and possibly ending, the opioid epidemic
entirely. Lastly, and most importantly, if states adopt the uniform
PDMP, physicians’ discretion and patient autonomy will be restored to
pre-epidemic levels that conform to the rights owed to both parties.
Overall, by adopting the uniform PDMP in its entirety, states have the
ability to strike a required, and much needed, balance between medical
decision-making, patient access, and combatting the opioid epidemic.

247. Durning, supra note 11, at 239.
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